TMDX

TransMedics Group, Inc. [TMDX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TMDX Stock Summary

Top 10 Correlated ETFs

TMDX

Top 10 Correlated Stocks

TMDX

In the News

TMDX Financial details

Company Rating
-
Market Cap
3B
Income
-25.03M
Revenue
241.62M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
584
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-78.11
Forward P/E
-
PEG
21
P/S
14.58
P/B
22.1
P/C
-
P/FCF
-118.69
Quick Ratio
9.93
Current Ratio
10.93
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
-37.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-20.07%
Revenue last 5Y
59.23%
Revenue Q/Q
22.19%
EPS Q/Q
-115.38%
-
-
-
-
SMA20
0.56%
SMA50
7.17%
SMA100
17.3%
Inst Own
-
Inst Trans
-
ROA
-5%
ROE
-22%
ROC
-0.06%
Gross Margin
66%
Oper. Margin
-20%
Profit Margin
-19%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
36.42-99.63
52W High
+24.73%
52W Low
+243%
RSI
39.53
Rel Volume
0.7
Avg Volume
696.83K
Volume
487.44K
Perf Week
-16.38%
Perf Month
-11.15%
Perf Quarter
0.97%
Perf Half Y
14.56%
-
-
-
-
Beta
2.001
-
-
Volatility
5.9%, 6.25%
Prev Close
1.79%
Price
123.48
Change
-3.86%

Something similar

Top by Market Cap
BRYN.DE
FB2A.DE
VTSAX
JPM
AMZN
Top Correlated ETFs
LGLV
HUSV
CWS
QLV
USML
Top Correlated Stocks
ELA
CSV
KNX
JBHT
Similar Market Cap
BPMC
NFTA.TA
4564.T
1220.TW
SAKHTISUG.NS

Company Profile

Healthcare Medical - Devices
  • Volume Average 696.83K
  • Market Capitalization 3B
  • Employee 584
  • CEO Dr. Waleed H. Hassanein M.D.
  • Headquarters Andover,MA,US
  • IPO Date 2019-05-02
  • Website https://www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.